Skip to main content
. 2018 May 21;13(5):e0196094. doi: 10.1371/journal.pone.0196094

Table 2. Incidence and adjusted hazard measures of pneumonia in association with acupuncture use by sex, age at first stroke and subtypes of stroke.

No use Acupuncture use Pneumonia risk
Events PY IR Events PY IR HR (95% CI)*
Full model 3825 64904 58.9 2971 55596 53.4 0.86 (0.82–0.90)
Sex
    Female 1473 28623 51.5 1009 24103 41.9 0.79 (0.70–0.82)
    Male 2352 36281 64.8 1962 31493 62.3 0.92 (0.86–0.98)
Age, years
    20–29 13 387 33.6 2 366 5.5 0.16 (0.04–0.69)
    30–39 31 956 32.4 15 839 17.9 0.52 (0.28–0.98)
    40–49 171 6839 25.0 112 5657 19.8 0.73 (0.58–0.93)
    50–59 486 14836 32.8 362 12364 29.3 0.83 (0.72–0.95)
    60–69 1254 23222 54.0 920 19532 47.1 0.82 (0.75–0.89)
    70–79 1553 16896 91.9 1257 14952 84.1 0.88 (0.81–0.95)
    ≥80 317 1769 179.2 303 1885 160.7 0.86 (0.73–1.00)
Subtypes of stroke
    Hemorrhagic 215 4310 49.9 147 4008 36.7 0.66 (0.53–0.81)
    Ischemic 2324 36768 63.2 1862 32254 57.7 0.86 (0.81–0.92)
    Others 1286 23826 54.0 962 19334 49.8 0.87 (0.80–0.95)
Medical conditions
    0 471 4285 109.9 307 5115 60.0 0.49 (0.43–0.57)
    1 971 14550 66.7 717 13006 55.1 0.77 (0.70–0.85)
    2 1021 17711 57.6 816 14964 54.5 0.92 (0.84–1.01)
    ≥3 1362 28539 48.0 1131 22511 50.2 1.10 (1.01–1.19)
Length of stay, days
    1–6 2420 44568 54.3 1820 36260 50.2 0.90 (0.84–0.95)
    ≥7 1405 20336 69.1 1151 19336 59.5 0.80 (0.74–0.87)

*Adjusted for all covariates listed in Table 1. The HR of pneumonia associated with acupuncture use is 0.86 (95% CI 0.82–0.91) in the additional full model adjusted all covariates listed in Table 1 plus suctioning, bacterial sensitivity test, general ward stay, nasogastric intubation, osmotherapy and urinary catheterization.

†In the sensitivity analysis, acupuncture was associated with reduced pneumonia risk after excluding pneumonia event in the 1 (OR 0.87, 95% CI 0.83–0.91), 3 (OR 0.88, 95% CI 0.84–0.93), 6 (OR 0.90, 95% CI 0.86–0.94), 9 (OR 0.91, 95% CI 0.86–0.95), 12 (OR 0.92, 95% CI 0.87–0.96) months during the follow-up period.